David Aguilera-Alonso (Spain)

Hospital Gregorio Marañón Pediatric Infectious Diseases
Medicine degree at University of Valencia (Spain), 2012. Specialist in Pediatrics at Hospital General de Valencia (Spain), 2013-2017. Subspeciality in Infectious Diseases. Master degree in Paediatric Infectious Diseases, Universidad Complutense (Madrid), 2017-2018. University degree in Statistics and Interpretation of Medical Studies, UNED University, 2014-2015. Attending physician in Pediatrics at Gregorio Marañón Hospital in Madrid, in the Infectious Diseases Unit, since 2019. Member of the Antimicrobial Stewardship at Gregorio Marañón Hospital in Madrid and of the Antimicrobial Stewardship in Ambulatory Health Care of Madrid. Investigator and co-investigator in multiple projects and clinical trials, including antimicrobial resistance, HIV infection, vaccines, viral respiratory infections, and tuberculosis. Author and co-author of several book chapters and multiple research papers. Board member of the Spanish Society of Paediatric Infectious Diseases (SEIP). Member of the European Society for Paediatric Infectious Diseases (ESPID), Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and Spanish Association of Pediatrics (AEP). Member of the ESPID-EUCAST joint taskforce on antibiotic dosing in children. Invited reviewer of BMC Infectious Diseases, Enfermedades Infecciosas y Microbiología Clínica, Anales de Pediatría. and Archivos de Bronconeumología.

Presenter of 2 Presentations

STAPHYLOCOCCUS AUREUS COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN AFTER PNEUMOCOCCAL 13-VALENT VACCINATION (2008-2018): COMPARISON WITH STREPTOCOCCUS PNEUMONIAE (NACSAPED STUDY) (ID 1102)

Lecture Time
10:44 - 10:51
Room
Hall 05

Abstract

Background

After introducing pneumococcal vaccination, the epidemiology of community-acquired pneumonia (CAP) in children has changed. Thus, the prevalence of non-pneumococcal bacteria, such as Staphylococcus aureus, may be increasing. Pneumococcal 13-valent vaccination was implemented in the Regional Immunization program of Madrid in 2010. We aimed to describe the epidemiology of pediatric S. aureus CAP (SA-CAP) in recent years and to compare them with the characteristics of Streptococcus pneumoniae CAP (SP-CAP).

Methods

Retrospective multicenter study including patients <17 years with bacterial CAP (S. aureus, S. pneumoniae, and Streptococcus pyogenes) admitted in 5 tertiary hospitals in Madrid (Spain) during 2008-18. For comparisons, S. pneumoniae CAP (SP-CAP) were randomly selected with a ratio 2:1 SA-CAP, comparing 34 SA-CAP with 68 SP-CAP. The annual rate of cases/10,000 admissions/year was analyzed.

Results

236/313(75.4%) bacterial pneumonia were SP-CAP, and 34/313(10.9%) SA-CAP. The annual rate of SP-CAP decreased from 14.7/10,000 admissions (2008) to 7.7/10,000 admissions (2018)(p<0.001), whereas the annual rate of SA-CAP remained stable(Figure). SP-CAP median age was higher (2.9[IQR: 1.7-4.6]years) than SA-CAP (0.7[IQR: 0.5-2.6]years)(p<0.001). Initial empiric treatment was more frequently inadequate in SA-CAP (50% vs. 1.5%,p<0.001). Viral coinfections were more commonly detected among SA-CAP(26.5% vs. 7.4%,p=0.008). A higher percentage of patients with SA-CAP required respiratory support. However, lung complications were more common among SP-CAP: pleural effusion(64.7 vs. 47.1%,p=0.088),p=0.088) and lung necrosis(32.4% vs. 5.9%,p=0.003).figure. changes in the epidemiology of bacterial pneumonia.png

Conclusions

The prevalence of SP-CAP in children decreased from 2008 to 2018, whereas S. pyogenes CAP prevalence slightly increased. Interestingly, in this population, unlike other studies, admitted SP-CAP had a higher severity than SA-CAP. Indeed, two patients with SP-CAP (2.9%) died vs. none SA-CAP.

Hide

STAPHYLOCOCCUS AUREUS COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN AFTER PNEUMOCOCCAL 13-VALENT VACCINATION (2008-2018): EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES (NACSAPED STUDY) (ID 2030)

Lecture Time
17:35 - 17:40
Room
Hall 02